Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table of Contents

Last Updated: December 6, 2022

Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

What’s New in the Guidelines

The COVID-19 Treatment Guidelines Panel’s Update on Bebtelovimab

Overview

  • Overview of COVID-19
  • Testing for SARS-CoV-2 Infection
  • Prevention of SARS-CoV-2 Infection
  • Clinical Spectrum of SARS-CoV-2 Infection
  • Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment of COVID-19 in Nonhospitalized Patients When There Are Logistical Constraints

Clinical Management of Adults

  • Clinical Management of Adults Summary
  • General Management of Nonhospitalized Adults With Acute COVID-19
  • Therapeutic Management of Nonhospitalized Adults With COVID-19
  • Therapeutic Management of Hospitalized Adults With COVID-19

Clinical Management of Children

  • Clinical Management of Children Summary
  • Special Considerations in Children
  • Therapeutic Management of Nonhospitalized Children With COVID-19
  • Therapeutic Management of Hospitalized Children With COVID-19
  • Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children (MIS-C) (With Discussion on Multisystem Inflammatory Syndrome in Adults [MIS-A])

Critical Care for Adults

  • Care of Critically Ill Adults With COVID-19 (Summary Recommendations)
  • Introduction to Critical Care Management of Adults With COVID-19
  • Hemodynamics for Adults
  • Oxygenation and Ventilation for Adults
  • Pharmacologic Interventions for Critically Ill Patients
  • Extracorporeal Membrane Oxygenation for Adults

Critical Care for Children

  • Introduction to Critical Care Management of Children With COVID-19
  • Hemodynamic Considerations for Children
  • Oxygenation and Ventilation for Children
  • Extracorporeal Membrane Oxygenation for Children

Antivirals, Including Antibody Products

  • Antiviral Agents, Including Antibody Products (Summary Recommendations)
  • Remdesivir
    • Table 4a. Remdesivir: Selected Clinical Data
  • Ritonavir-Boosted Nirmatrelvir (Paxlovid)
    • Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
  • Molnupiravir
    • Anti-SARS-CoV-2 Monoclonal Antibodies
      • Table 4b. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
    • COVID-19 Convalescent Plasma
      • Table 4c. COVID-19 Convalescent Plasma: Selected Clinical Data
    • Interferons
      • Table 4d. Interferons: Selected Clinical Data
    • Table 4e. Characteristics of Antiviral Agents, Including Antibody Products

    Immunomodulators

    • Immunomodulators (Summary Recommendations)
    • Corticosteroids
      • Table 5a. Systemic Corticosteroids: Selected Clinical Data
      • Table 5b. Inhaled Corticosteroids: Selected Clinical Data
    • Interleukin-6 Inhibitors
      • Table 5c. Interleukin-6 Inhibitors: Selected Clinical Data
    • Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors
      • Table 5d. Kinase Inhibitors: Selected Clinical Data
    • Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
      • Table 5e. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
    • Interleukin-1 Inhibitors
    • Table 5f. Characteristics of Immunomodulators

    Antithrombotic Therapy in Patients With COVID-19

    • Table 6a. Anticoagulant Therapy: Selected Clinical Data
    • Table 6b. Antiplatelet Therapy: Selected Clinical Data

    Miscellaneous Drugs

    • Miscellaneous Drugs (Summary Recommendations)
    • Colchicine
    • Fluvoxamine
      • Table 7a. Fluvoxamine: Selected Clinical Data
    • Intravenous Immunoglobulin
    • Ivermectin
      • Table 7b. Ivermectin: Selected Clinical Data
    • Metformin
      • Table 7c. Metformin: Selected Clinical Data
    • Table 7d. Characteristics of Miscellaneous Drugs

    Supplements

    • Supplements (Summary Recommendations)
    • Vitamin C
    • Vitamin D
    • Zinc

    Considerations for Using Concomitant Medications in Patients With COVID-19

    Special Populations

    • Special Considerations in People Who Are Immunocompromised
    • Special Considerations in Adults and Children With Cancer
    • Special Considerations in Solid Organ Transplant, Hematopoietic Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients
    • Special Considerations in Pregnancy
    • Influenza and COVID-19
    • Special Considerations in People With HIV

    Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members

    Appendix A, Table 2. COVID-19 Treatment Guidelines Panel Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics